RhumbLine Advisers’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-66,344
| Closed | -$105K | – | 4410 |
|
|
2024
Q1 | $105K | Buy |
66,344
+1,478
| +2% | +$2.35K | ﹤0.01% | 3433 |
|
|
2023
Q4 | $55.7K | Hold |
64,866
| – | – | ﹤0.01% | 3612 |
|
|
2023
Q3 | $69.4K | Buy |
64,866
+2,811
| +5% | +$3.01K | ﹤0.01% | 3571 |
|
|
2023
Q2 | $161K | Buy |
62,055
+6,363
| +11% | +$16.5K | ﹤0.01% | 3348 |
|
|
2023
Q1 | $227K | Buy |
55,692
+985
| +2% | +$4.02K | ﹤0.01% | 2709 |
|
|
2022
Q4 | $275K | Buy |
54,707
+541
| +1% | +$2.72K | ﹤0.01% | 2707 |
|
|
2022
Q3 | $708K | Buy |
54,166
+4,249
| +9% | +$55.5K | ﹤0.01% | 2332 |
|
|
2022
Q2 | $640K | Buy |
49,917
+10,111
| +25% | +$130K | ﹤0.01% | 2360 |
|
|
2022
Q1 | $607K | Sell |
39,806
-2,720
| -6% | -$41.5K | ﹤0.01% | 2334 |
|
|
2021
Q4 | $753K | Sell |
42,526
-411
| -1% | -$7.28K | ﹤0.01% | 2334 |
|
|
2021
Q3 | $903K | Buy |
42,937
+2,107
| +5% | +$44.3K | ﹤0.01% | 2269 |
|
|
2021
Q2 | $805K | Buy |
40,830
+12,338
| +43% | +$243K | ﹤0.01% | 2341 |
|
|
2021
Q1 | $828K | Sell |
28,492
-860
| -3% | -$25K | ﹤0.01% | 2276 |
|
|
2020
Q4 | $889K | Buy |
29,352
+1,877
| +7% | +$56.9K | ﹤0.01% | 2192 |
|
|
2020
Q3 | $437K | Sell |
27,475
-4,116
| -13% | -$65.5K | ﹤0.01% | 2349 |
|
|
2020
Q2 | $624K | Buy |
31,591
+5,196
| +20% | +$103K | ﹤0.01% | 2252 |
|
|
2020
Q1 | $325K | Buy |
26,395
+2,939
| +13% | +$36.2K | ﹤0.01% | 2369 |
|
|
2019
Q4 | $434K | Buy |
+23,456
| New | +$434K | ﹤0.01% | 2425 |
|